Additionally, a phase II, single-arm, multicenter prospective ALNEO study is ongoing to evaluate the efficacy and safety of alectinib as neoadjuvant therapy in surgically resectable stage III ALK-positive NSCLC (Leonetti et al., 2021). This evidence concerns the gene ALK and non-small cell lung carcinoma.